Physician profile
Wael Taha
NPI 1578501748
$12,019.85
in general payments reported to CMS, 2019-2025
35 companies · $2,064 in 2025
The $2,064 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,591 · 2020: $367 · 2021: $160 · 2022: $278 · 2023: $2,233 · 2024: $326 · 2025: $2,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,370 · Food and Beverage: $1,771 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $432 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,370.35 |
| Food and Beverage | $1,770.57 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $432.00 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $3,626.96 | 2019-2020 | |
| Medtronic, INC. | $2,173.37 | 2022-2025 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Medtronic Minimed, INC. | $1,888.05 | 2019-2020 | |
| Synthes Gmbh | $1,798.00 | 2023 | |
| Novo Nordisk INC | $416.63 | 2019-2025 | Ozempic, Wegovy |
| Amgen INC. | $290.36 | 2019-2025 | Evenity, Prolia, Tepezza |
| Neurocrine Biosciences, INC. | $188.17 | 2024-2025 | |
| Lilly USA, LLC | $186.18 | 2019-2024 | Jardiance |
| Radius Health, INC. | $177.54 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $162.52 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $115.62 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $98.08 | 2019 | |
| Pfizer INC. | $90.74 | 2019-2025 | |
| Madrigal Pharmaceuticals | $79.34 | 2025 | Rezdiffra |
| Abbott Laboratories | $73.83 | 2023-2024 | Freestyle Insulinx, Freestyle Libre 3 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $67.59 | 2019-2020 | |
| Dexcom, INC. | $56.63 | 2021-2023 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $51.44 | 2020-2025 | Isturisa |
| Amarin Pharma, INC. | $46.68 | 2020-2021 | |
| Shire North American Group INC | $46.15 | 2019 | |
| Horizon Therapeutics Plc | $45.57 | 2019-2020 | |
| Sequel Med Tech, LLC | $37.93 | 2025 | Twiist |
| Insulet Corporation | $33.64 | 2019 | |
| Alexion Pharmaceuticals, INC. | $31.30 | 2019 | |
| Sanofi-Aventis U.S. LLC | $30.64 | 2022 | |
| Exact Sciences Corporation | $28.73 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $28.55 | 2020 | |
| Ascendis Pharma Endocrinology INC | $28.02 | 2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $24.18 | 2024 | Gvoke Hypopen |
| Zealand Pharma US, INC. | $19.64 | 2021 | |
| Antares Pharma, INC. | $18.28 | 2025 | Xyosted |
| Janssen Biotech, INC. | $16.95 | 2019 | |
| Viiv Healthcare Company | $16.06 | 2025 | Apretude |
| Arbor Pharmaceuticals, INC. | $13.30 | 2019 | |
| Cardiovascular Systems INC. | $13.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wael Taha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.